Giancarlo Agnelli

Sort by:

Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC).

Adam Torbicki, A Perrier, +11 authors Jean-Pierre Bassand
European heart journal
2008

Non-thrombotic PE does not represent a distinct clinical syndrome. It may be due to a variety of embolic materials and result in a wide spectrum of clinical presentations, making the diagnosis… (More)

Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Clive Kearon, Susan R. Kahn, Giancarlo Agnelli, Samuel Z. Goldhaber, Gary E. Raskob, Anthony James Comerota
Chest
2008

This chapter about treatment for venous thromboembolic disease is part of the American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Grade 1 recommendations… (More)

Oral rivaroxaban for symptomatic venous thromboembolism.

Rupert Martin Bauersachs, Scott D. Berkowitz, +16 authors Sebastian W Schellong
The New England journal of medicine
2010

BACKGROUND Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without the need for… (More)

ESC Guidelines on the diagnosis and management of acute pulmonary embolism

Adam Torbicki, Giancarlo Agnelli, +18 authors Massimo Francesco Piepoli
2014

Authors/Task Force Members: Stavros Konstantinides* (Chairperson) (Germany/ Greece), Adam Torbicki* (Co-chairperson) (Poland), Giancarlo Agnelli (Italy), Nicolas Danchin (France), David Fitzmaurice… (More)

Oral apixaban for the treatment of acute venous thromboembolism.

Giancarlo Agnelli, Harry R. Buller, +8 authors Jeffrey I Weitz
The New England journal of medicine
2013

BACKGROUND Apixaban, an oral factor Xa inhibitor administered in fixed doses, may simplify the treatment of venous thromboembolism. METHODS In this randomized, double-blind study, we compared… (More)

Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

HarryR. Büller, Giancarlo Agnelli, Russel D. Hull, Thomas M. Hyers, Martin H. Prins, Gary E. Raskob
Chest
2004

This chapter about antithrombotic therapy for venous thromboembolic disease is part of the seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence Based Guidelines. Grade 1… (More)

Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality.

Alexander A. Cohen, Giancarlo Agnelli, +11 authors Michael Spannagl
Thrombosis and haemostasis
2007

Venous thromboembolism (VTE) is often asymptomatic, mis-diagnosed, and unrecognized at death, and there is a lack of routine postmortem examinations. These factors are thought to result in marked… (More)

Apixaban for extended treatment of venous thromboembolism.

Giancarlo Agnelli, Harry R. Buller, +6 authors Jeffrey I Weitz
The New England journal of medicine
2013

BACKGROUND Apixaban, an oral factor Xa inhibitor that can be administered in a simple, fixed-dose regimen, may be an option for the extended treatment of venous thromboembolism. METHODS In this… (More)

2014 ESC Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism

Stavros V. Konstantinides, Adam Torbicki, +21 authors Maurizio Zompatori
2015

Fibrinolysis for patients with intermediate-risk pulmonary embolism.

Guy Meyer, Éric Vicaut, +34 authors Stavros V. Konstantinides
The New England journal of medicine
2014

BACKGROUND The role of fibrinolytic therapy in patients with intermediate-risk pulmonary embolism is controversial. METHODS In a randomized, double-blind trial, we compared tenecteplase plus… (More)

Filter Results:

Publication Year

Publication Type

Co-author

Journals and Conferences